Sherri Smith

726 total citations
18 papers, 329 citations indexed

About

Sherri Smith is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Sherri Smith has authored 18 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Pharmacology and 5 papers in Oncology. Recurrent topics in Sherri Smith's work include Pharmacogenetics and Drug Metabolism (6 papers), Fibroblast Growth Factor Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). Sherri Smith is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Fibroblast Growth Factor Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). Sherri Smith collaborates with scholars based in United States, Canada and Switzerland. Sherri Smith's co-authors include Nigel J. Waters, John A. Smith, Michael Klagsbrun, Joachim Sasse, Yuen Shing, Shawn M. Davidson, Robert Sullivan, Michael E. Charness, Michael F. Wilkemeyer and Richard Chesworth and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Annals of Oncology.

In The Last Decade

Sherri Smith

13 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sherri Smith United States 7 186 48 48 44 28 18 329
Mailin Li United States 9 188 1.0× 39 0.8× 57 1.2× 34 0.8× 22 0.8× 12 335
Mehri Khatami Iran 13 267 1.4× 20 0.4× 29 0.6× 18 0.4× 11 0.4× 58 438
Somesh Choudhury United States 11 278 1.5× 41 0.9× 67 1.4× 41 0.9× 19 0.7× 15 625
Tess V. Dupre United States 10 141 0.8× 34 0.7× 33 0.7× 23 0.5× 10 0.4× 13 322
Simon Byrne United Kingdom 11 158 0.8× 45 0.9× 28 0.6× 37 0.8× 13 0.5× 21 384
Adam Elwi Canada 10 180 1.0× 42 0.9× 121 2.5× 25 0.6× 8 0.3× 20 369
Kayoko Kojima Japan 9 207 1.1× 55 1.1× 59 1.2× 31 0.7× 22 0.8× 11 458
Noriko Matsunaga Japan 12 199 1.1× 24 0.5× 65 1.4× 32 0.7× 10 0.4× 29 404
Laëtitia Gorisse France 12 205 1.1× 11 0.2× 28 0.6× 70 1.6× 14 0.5× 21 464
Martine Duval Canada 7 215 1.2× 13 0.3× 67 1.4× 30 0.7× 12 0.4× 15 427

Countries citing papers authored by Sherri Smith

Since Specialization
Citations

This map shows the geographic impact of Sherri Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherri Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherri Smith more than expected).

Fields of papers citing papers by Sherri Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherri Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherri Smith. The network helps show where Sherri Smith may publish in the future.

Co-authorship network of co-authors of Sherri Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Sherri Smith. A scholar is included among the top collaborators of Sherri Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherri Smith. Sherri Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lucas, Matthew C., Melinda S. Merchant, Matthew O’Connor, et al.. (2022). 27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models. Annals of Oncology. 33. S14–S14. 5 indexed citations
2.
Lucas, Matthew C., Melinda S. Merchant, Matthew J. O’Connor, et al.. (2022). Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models. European Journal of Cancer. 174. S23–S23.
3.
Lucas, Matthew C., Melinda S. Merchant, Matthew O’Connor, et al.. (2022). BDTX-1535, a fourth generation EGFR inhibitor, targeting intrinsic and acquired resistance mutations in NSCLC. European Journal of Cancer. 174. S22–S22. 1 indexed citations
4.
Dardenne, Étienne, Shao Ning Yang, Ahmet Mentes, et al.. (2021). 35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers. Annals of Oncology. 32. S15–S15. 1 indexed citations
5.
6.
Rioux, Nathalie, Sherri Smith, Amy Kim, et al.. (2020). Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. Xenobiotica. 50(9). 1101–1114. 3 indexed citations
7.
Smith, Sherri, Manav Korpal, Sudeep Prajapati, et al.. (2019). In vitro-in vivo correlation of clearance for H3B-5942, a novel selective erα covalent antagonist (SERCA). Drug Metabolism and Pharmacokinetics. 34(1). S22–S22.
8.
9.
Rioux, Nathalie, Sherri Smith, Manav Korpal, et al.. (2018). Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). Cancer Chemotherapy and Pharmacology. 83(1). 151–160. 14 indexed citations
10.
Smith, Sherri & Nigel J. Waters. (2018). Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein. Pharmaceutical Research. 36(2). 30–30. 100 indexed citations
11.
12.
Smith, Sherri, Benjamin Suttle, Vincent Ribrag, et al.. (2016). Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors. Cancer Research. 76(14_Supplement). CT029–CT029. 2 indexed citations
13.
14.
Waters, Nigel J., Sherri Smith, Edward J. Olhava, et al.. (2015). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology. 77(1). 43–62. 23 indexed citations
15.
Mitchell, Lorna H., P. Ann Boriack‐Sjodin, Sherri Smith, et al.. (2015). Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability. Molecular Cancer Therapeutics. 14(12_Supplement_2). C85–C85.
16.
Adams, Christopher M., Arco Y. Jeng, Rajeshri G. Karki, et al.. (2010). The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase. Bioorganic & Medicinal Chemistry Letters. 20(15). 4324–4327. 10 indexed citations
17.
Wilkemeyer, Michael F., et al.. (2000). Antagonists of alcohol inhibition of cell adhesion. Proceedings of the National Academy of Sciences. 97(7). 3690–3695. 50 indexed citations
18.
Klagsbrun, Michael, Sherri Smith, Robert Sullivan, et al.. (1987). Multiple forms of basic fibroblast growth factor: amino-terminal cleavages by tumor cell- and brain cell-derived acid proteinases.. Proceedings of the National Academy of Sciences. 84(7). 1839–1843. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mailin Li Breakdown of academic impact, for papers by Mehri Khatami Breakdown of academic impact, for papers by Somesh Choudhury Breakdown of academic impact, for papers by Tess V. Dupre Breakdown of academic impact, for papers by Simon Byrne Breakdown of academic impact, for papers by Adam Elwi Breakdown of academic impact, for papers by Kayoko Kojima Breakdown of academic impact, for papers by Noriko Matsunaga Breakdown of academic impact, for papers by Laëtitia Gorisse Breakdown of academic impact, for papers by Martine Duval
Rankless by CCL
2026